Covid-19 (Temas de Saúde Pública)
O que influencia as respostas das pessoas às mensagens de saúde pública para o controle de riscos e prevenção de doenças infecciosas? Uma breve revisão sistemática das evidências e recomendações.
15 Nov, 2021 | 13:57h
Comentário no Twitter
COVID-19 messages should:
1) be developed with communities
2) address uncertainty immediately + with transparency
3) focus on unifying messages from sources
4) frame messages aimed at increasing understanding, social responsibility + ind control https://t.co/faxtAgngAI— Caroline Tomes MFPH (@carotomes) November 12, 2021
De acordo com estudo, vacinas contra SARS-CoV-2 são seguras e imunogênicas na maioria das pessoas com câncer.
15 Nov, 2021 | 13:56hComunicado de imprensa: SARS-CoV-2 vaccines are safe and immunogenic in most people with cancer, according to study – Harvard Medical School
Estudo original: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study – Journal of Clinical Oncology
Comentário do autor no Twitter (fio – clique para saber mais)
The CANVAX study is out in @JCO_ASCO! https://t.co/WKrU6dQIEB
Grateful to >1000 CANVAX participants, study leads ( @JustinGainor, @MGHPathology, @BalazsLab) and so many co-authors incl. @arthur_kim_ID, @KimberlyBlumen1, @joanhowMD, @dradityabardia
Much more to come!— Vivek Naranbhai, MD, PhD, DPhil (@vivek_naranbhai) November 10, 2021
Estudo randomizado | BBV152 (vacina indiana COVAXIN) tem uma eficácia geral de 77,8% contra Covid-19 sintomática em adultos.
12 Nov, 2021 | 13:51hComentário convidado: Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 – The Lancet
Conteúdo relacionado: WHO issues emergency use approval for India’s Covaxin.
Comentário no Twitter
NEW—Interim data from a phase 3 trial of #BBV152, a COVID-19 vaccine developed in India, suggests it is safe and two doses offer 77.8% protection against symptomatic #COVID19. https://t.co/QWtz0AWd1X
— The Lancet (@TheLancet) November 11, 2021
Mortes de crianças e jovens na Inglaterra após infecção por SARS-CoV-2 durante o 1º ano da pandemia – “Ao todo, 99,995% das crianças e jovens com teste positivo para SARS-CoV-2 sobreviveram.”
12 Nov, 2021 | 13:48hConteúdo relacionado:
Study: Children and young people remain at low risk of COVID-19 mortality
Comentários no Twitter
Just published @NatureMedicine
An in-depth analysis of the 25 children who died from Covid in England during the 1st year of the pandemichttps://t.co/QK3gk1BXy5
Great that 99.995% of children w/ a positive test survived (not what is driving the need for 💉in kids) pic.twitter.com/moXKl8ysmA— Eric Topol (@EricTopol) November 11, 2021
A clinical review of all pediatric deaths in England from March 2020 to February 2021 attributes 25 deaths to SARS-CoV-2 infection and identifies risk factors to guide interventions, according to a @NatureMedicine article. https://t.co/Bpjhf5sgow pic.twitter.com/v24Zf9CsXK
— Nature Portfolio (@NaturePortfolio) November 11, 2021
Aumento da imunidade às vacinas contra COVID-19 – “Novos estudos destacam os benefícios imunológicos dos reforços da vacina contra COVID-19, mas ainda restam questões sobre como fazer o melhor uso de suprimentos globais limitados.”
12 Nov, 2021 | 13:46hBoosting immunity to COVID-19 vaccines – Nature Medicine
Mapa | O mundo segundo a cobertura vacinal contra Covid.
12 Nov, 2021 | 13:43hThe world according to covid vaccine coverage – The BMJ
Comentário no Twitter
A year since the first covid vaccines were announced, rollouts are under way all over the world—to differing degrees.
This map shows the percentage of national population to have received two doses of covid vaccinehttps://t.co/rIU3qeWXIK @munkeatlooi pic.twitter.com/zZHr1XXBe8
— The BMJ (@bmj_latest) November 11, 2021
Vigilância global, pesquisa e colaboração necessárias para aprimorar a compreensão e o tratamento da “long COVID”.
12 Nov, 2021 | 13:42hConteúdos relacionados:
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)
Diretrizes IDSA sobre prevenção de infecção para profissionais de saúde que cuidam de pacientes com COVID-19 suspeitada ou conhecida.
11 Nov, 2021 | 16:25h
Comentário no Twitter
New recommendation on the use of eye protection as well as revised recommendations and literature on the use of PPE now available in IDSA’s COVID-19 Infection Prevention Guideline: https://t.co/MiACvSoG92#COVID19Guidelines pic.twitter.com/Zp7s0Ely9J
— IDSA (@IDSAInfo) November 5, 2021
Pílulas antivirais contra COVID: o que os cientistas ainda precisam saber – “Medicações como molnupiravir e paxlovid podem mudar o curso da pandemia se os resultados de ensaios clínicos se repetirem no mundo real.”
11 Nov, 2021 | 16:23hCOVID antiviral pills: what scientists still want to know – Nature
Conteúdos relacionados:
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
Perspectiva | Como será o fim da pandemia: cientistas têm pistas sobre a evolução do SARS-CoV-2.
11 Nov, 2021 | 16:20hCOVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed – NPR